Systemic Immunity Is Required for Effective Cancer Immunotherapy

[1]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[2]  S. Kwek,et al.  GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses , 2016, Oncoimmunology.

[3]  G. Nolan,et al.  Coordinate actions of innate immune responses oppose those of the adaptive immune system during Salmonella infection of mice , 2016, Science Signaling.

[4]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[5]  Sean C. Bendall,et al.  An interactive reference framework for modeling a dynamic immune system , 2015, Science.

[6]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[7]  Edgar G. Engleman,et al.  Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity , 2015, Nature.

[8]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[9]  Eli R. Zunder,et al.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[10]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[11]  S. Rosenberg.  Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment , 2014, Nature Reviews Clinical Oncology.

[12]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[13]  R. Tibshirani,et al.  Automated identification of stratifying signatures in cellular subpopulations , 2014, Proceedings of the National Academy of Sciences.

[14]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[15]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[16]  G. Plitas,et al.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy , 2013, The Journal of experimental medicine.

[17]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[18]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[19]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[20]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[21]  T. Malek,et al.  IL-2 Receptor Signaling Is Essential for the Development of Klrg1+ Terminally Differentiated T Regulatory Cells , 2012, The Journal of Immunology.

[22]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[23]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[24]  T. Strutt,et al.  Expanding roles for CD4+ T cells in immunity to viruses , 2012, Nature Reviews Immunology.

[25]  T. Ideker,et al.  Differential network biology , 2012, Molecular systems biology.

[26]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[27]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[28]  C. Alam,et al.  Ly6C supports preferential homing of central memory CD8+ T cells into lymph nodes , 2011, European journal of immunology.

[29]  N. Fazilleau,et al.  Plasma cells negatively regulate the follicular helper T cell program , 2010, Nature Immunology.

[30]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[31]  P. Muranski,et al.  Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma , 2010, The Journal of experimental medicine.

[32]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[33]  Mathieu Bastian,et al.  Gephi: An Open Source Software for Exploring and Manipulating Networks , 2009, ICWSM.

[34]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[35]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[36]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Haeryfar,et al.  Thy-1: More than a Mouse Pan-T Cell Marker1 , 2004, The Journal of Immunology.

[38]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[39]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[40]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[41]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.

[42]  William B. Colev.  I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1893 .

[43]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[44]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[45]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .